Price and utilization of statins in the medicaid program

Drug Benefit Trends

Volumn 18, Issue 11, 2006, Pages 580-592

  Jing, Yonghua ^a   Kelton, Christina M L ^a   Guo, Jeff J ^a   Chen, Yan ^a   Li, Xing ^a   Wigle, Patricia R ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cost; Expenditure; Medicaid; Statins; Utilization

Indexed keywords

EID: 33846680218     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. American Heart Association. Heart attack and angina statistics. Available at: www.americanheart.org/presenter.jhtml?identifier=4591. Accessed October 4, 2006.
2. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97:946-952.
3. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
5. Marks JW. Niacin. Available at: www. medicinenet.com/niacin/article.htm. Accessed October 4, 2006.
6. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extendedrelease/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. 2003;91:667-672.
7. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290: 197]. JAMA. 2003;289:2560-2572.
8. Ohio Job & Family Services. Ohio Medicaid Drug List. Available at: http://medlist.ohio.gov/main-domain/home.jsf. Accessed October 11, 2006.
9. First Health Services Corporation. New York State Medicaid Preferred Drug List. Available at: https://newyork.fhsc.com. Accessed October 11, 2006.
10. Herper M, Kang P. World's 10 best-selling drugs. March 28, 2006. Available at: www.wired.com/news/technology/0,70508-0.html. Accessed October 4, 2006.
11. Stagnitti MN. Top 10 outpatient prescription medicines ranked by utilization and expenditures for the elderly in the US community population, 2002. Statistical Brief 66. February 2005. Rockville, Md: Agency for Healthcare Research and Quality. Available at: www.meps.ahrq.gov/mepsweb/data-stats/Pub- ProdResults-Details.jsp?pt=Statistical%20Brief&opt=2&id=663. Accessed October 4, 2006.
12. IMS Health. Annual report on prescription drug trends. February 14, 2005. Available at: www.imshealth.com. Accessed October 4, 2006.
13. Jing Y, Chen Y, Kelton CML, Guo JJ. Trend analysis of price and utilization of statin drugs in US Medicaid programs. Presented at: 11th Annual International Meeting for the International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2006; Philadelphia.
14. 100 Leading national advertisers special report: profiles supplement. Advertising Age. June 26, 2006. Available at: www.adage.com. Accessed October 11, 2006.
15. Advertising Age Data Center. Top 200 megabrands ranked by total measured US advertising spending for the first half of 2005. Available at: www.adage.com. Accessed September 13, 2006.
16. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs 2000. Oslo: World Health Organization; 2000.
17. Miller GM, Stagnitti M. Trends in statin use in the civilian noninstitutionalized Medicare population, 1997 and 2002. Statistical Brief 97. Agency for Healthcare Research and Quality. September 2005. Available at: http://meps.ahrq.gov/mepsweb/data-stats/Pub-ProdResults-Details.jsp?pt= Statistical%20Brief&opt=2&id=711. Accessed October 4, 2006.
18. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294:1773-1781.
19. Consumers Union. Consumer Reports, Best Buy Drugs. Treating elevated cholesterol and heart disease - the statins. Available at: www.CRBestBuyDrugs. org. Accessed October 4, 2006.
20. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dL and C-reactive protein <2 mg/L: an analysis of the PROVE IT-TIMI-22 Trial. J Am Coll Cardiol. 2005;45:1644-1648.
21. Ray KK, Cannon CP, McCabe CH, et al; PROVE IT-TIMI 22 investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol. 2006;46:1405-1410.
22. Kaiser Family Foundation. Impact of direct-to-consumer advertising on prescription drug spending. Menlo Park, Calif; Kaiser Family Foundation: 2003. Available at: www.kff.org/rxdrugs/6084-index.cfm. Accessed October 6, 2006.
23. 11th Annual Report on DTC. Med Ad News. June 2005. Available at: pharmalive.com/magazines/medad/view.cfm?articleID=2240. Accessed October 6, 2006.
24. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92(4B):23K-29K.
25. Evans M, Rees A. Effects of HMG-CoAreductase inhibitors on skeletal muscle: are all statins the same? Drug Saf. 2002;25:649-663.
26. Bureau of Labor Statistics. Commodity data. Preparations, Ethical (Prescription) Series, 1991-2000, and Pharmaceutical Preparations, 2001-2005. Available at: www.bls.gov. Accessed October 6, 2006.
27. Elzinga KG, Mills DE. The distribution and pricing of prescription drugs. Int J Econ Business. 1997;4:287-299.
28. Abramson RG, Harrington CA, Missmar R, et al. Generic drug cost containment in Medicaid: lessons from five state MAC programs. Health Care Financ Rev. 2004;25:25-34. (Pubitemid 38728983)
29. Perreault S, Hamilton VH, Lavoie F, Grover S. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective? Arch Intern Med. 1998;158:375-381.
30. Moghadasian MH, Mancini GB, Frohlich JJ. Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin Pharmacother. 2000;1:683-695.
31. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol lowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132:769-779.
32. Pickin DM, McCabe CJ, Ramsay LE, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 1999;82:325-332.
33. Frank RG, Conti RM, Goldman HH. Mental health policy and psychotropic drugs. Milbank Q. 2005;83:271-298.
34. Kelton CML, Guo JJ, Ferrand Y, et al. Analysis of pharmaceutical products with large price changes in a regional hospital system. Presented at: 2nd Asia-Pacific Conference, International Society for Pharmacoeconomics and Outcomes Research; March 5-7, 2006; Shanghai.
35. Winslow R. New prescription for Zocor users. Wall Street Journal. June 17, 2006. Available at: www.wsj.com. Accessed October 6, 2006.
36. Tesoriero HW. Merck will sell Zocor below price of generics. Wall Street Journal. June 22, 2006. Available at: www.wsj.com. Accessed October 6, 2006.
37. Express Scripts Drug Trend Report 2004. Available at: www.express-scripts.com/ourcompany/news/industryreports. Accessed October 6, 2006.
38. Mitka M. Are OTC statins ready for prime time? JAMA. 2004;292:317-318.
39. FDA. Mevacor OTC switch could be topic of tentatively set NDAC and Endocrine & Metabolism Committee Meeting. October 22, 2004. Available at: www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee. Accessed October 6, 2006.
40. Mevacor daily OTC switch rejected based on patient inability to self select. January 14, 2005. Available at: www.thepinksheet.com/FDC/ AdvisoryCommittee/Committees/Nonprescription+Drugs/011405-Mevacor2/ 011405-MevacorR2.htm. Accessed October 6, 2006.